Article:
“Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer”
de Streel G et al 2021.
This video is a presentation that I held to the class in the seminar course in immunotherapy as part of my second degree in biology (it is in the Hebrew language). The subject was first demonstrated in an earlier job, by the group of de Streel G et al (from the current article of this presentation in this video) that published a good video demonstrating the main idea behind the TGF-β1 mechanism in this current trial besides the PD-1/PDl-1.
In this current trial, is being demonstration the reciprocal effect of targeting two cancer mechanisms at the same time or in other word, attacking the cancer cells from more that one front.
Targeting Cancer-T-Killer by a mediated inhibition of the “PD-1/PD-L1”, a mechanism (or pathway) that became blocked (resistance) and combining it with selective inhibition of “TGF-β1” pathway by targeting Cancer-T-Helper, that both, yielding an higher outcome in cancer treatment.
Links:
